Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Trial

<< Previous

Bullboard Posts

Next >>

Comment by KayakerBCon Nov 25, 2021 12:31pm

178 Views

Post# 34165557

RE:RE:Trial

If there will be no trial, Eversana wouldn't be hiring a Medical Science Liaison to deal with clinicians etc to advance apabetalone as a therapy for patients infected with COVID-19. And since they are partnered with Resverlogix, they have more info about the trial going forward. It says something about their confidence in the science and the trial. And Resverlogix won't give you any info about the trial start in an email. It's material information. (Yes, I get that the trial is waaaaaaaaaay late and it's annoying.)

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment